tetano
Editor, Senior Moderator
Influenza Other Respir Viruses
. 2024 Sep;18(9):e70002.
doi: 10.1111/irv.70002. Comparison of the Effectiveness of Baloxavir and Oseltamivir in Outpatients With Influenza B
Takahiro Takazono[SUP] 1 2 [/SUP], Genta Ito[SUP] 3 [/SUP], Naoki Hosogaya[SUP] 4 [/SUP], Naoki Iwanaga[SUP] 1 [/SUP], Takuji Komeda[SUP] 3 [/SUP], Masayuki Kobayashi[SUP] 3 [/SUP], Yoshitake Kitanishi[SUP] 3 [/SUP], Eriko Ogura[SUP] 5 [/SUP], Hiroshi Mukae[SUP] 1 6 [/SUP]
Affiliations
This retrospective cohort study analyzed data from a Japanese health insurance database to assess the effectiveness of baloxavir (n = 4822) for preventing severe events compared with oseltamivir (n = 10,523) in patients with influenza B. The primary endpoint was hospitalization incidence (Days 2-14). The secondary endpoints included intravenous antibacterial drug use, pneumonia hospitalization, heart failure hospitalization, inhalational oxygen requirement, and use of other anti-influenza drugs. The hospitalization incidence was significantly lower with baloxavir (0.15% vs. 0.37%; risk ratio: 2.48, 95% confidence interval: 1.13-5.43). Pneumonia and additional anti-influenza therapy were also less frequent with baloxavir, thus supporting its use. Trial Registration: UMIN Clinical Trials Registry Study ID: UMIN000051382.
Keywords: Japanese; baloxavir; database; hospitalization; influenza; oseltamivir.
. 2024 Sep;18(9):e70002.
doi: 10.1111/irv.70002. Comparison of the Effectiveness of Baloxavir and Oseltamivir in Outpatients With Influenza B
Takahiro Takazono[SUP] 1 2 [/SUP], Genta Ito[SUP] 3 [/SUP], Naoki Hosogaya[SUP] 4 [/SUP], Naoki Iwanaga[SUP] 1 [/SUP], Takuji Komeda[SUP] 3 [/SUP], Masayuki Kobayashi[SUP] 3 [/SUP], Yoshitake Kitanishi[SUP] 3 [/SUP], Eriko Ogura[SUP] 5 [/SUP], Hiroshi Mukae[SUP] 1 6 [/SUP]
Affiliations
- PMID: 39189087
- DOI: 10.1111/irv.70002
This retrospective cohort study analyzed data from a Japanese health insurance database to assess the effectiveness of baloxavir (n = 4822) for preventing severe events compared with oseltamivir (n = 10,523) in patients with influenza B. The primary endpoint was hospitalization incidence (Days 2-14). The secondary endpoints included intravenous antibacterial drug use, pneumonia hospitalization, heart failure hospitalization, inhalational oxygen requirement, and use of other anti-influenza drugs. The hospitalization incidence was significantly lower with baloxavir (0.15% vs. 0.37%; risk ratio: 2.48, 95% confidence interval: 1.13-5.43). Pneumonia and additional anti-influenza therapy were also less frequent with baloxavir, thus supporting its use. Trial Registration: UMIN Clinical Trials Registry Study ID: UMIN000051382.
Keywords: Japanese; baloxavir; database; hospitalization; influenza; oseltamivir.